SETD1B

📖 Wiki Page

gene3299 wordssynced 2026-04-02

SETD1B

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SETD1B</th>
</tr>
<tr>
<td class="label">Full Name</td>
<td>SET Domain Containing 1B, Histone Lysine Methyltransferase</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SETD1B</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>KMT2G, SET1B</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>12q24.31</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein-coding</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[612052](https://omim.org/entry/612052)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>[Q9BRL5](https://www.uniprot.org/uniprot/Q9BRL5)</td>
</tr>
<tr>
<td class="label">HGNC</td>
<td>[29165](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29165)</td>
</tr>
<tr>
<td class="label">Entrez Gene</td>
<td>[67243](https://www.ncbi.nlm.nih.gov/gene/67243)</td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td>[ENSG00000146070](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000146070)</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Function</td>
</tr>
<tr>
<td class="label">WDR5</td>
<td>Scaffold protein</td>
</tr>
<tr>
<td class="label">RBBP5</td>
<td>Core component</td>
</tr>
<tr>
<td class="label">ASH2L</td>
<td>Complex stability</td>
</tr>
<tr>
<td class="label">DPY30</td>
<td>Core component</td>
</tr>
<tr>
<td class

...

SETD1B

SETD1B

</div>

Overview

SETD1B (SET Domain Containing 1B) is a human gene encoding a histone H3 lysine 4 (H3K4) methyltransferase that functions as the catalytic subunit of the COMPASS (Complex of Proteins Associated with Set1) complex. Located on chromosome 12q24.31, SETD1B catalyzes trimethylation of histone H3 at lysine 4 (H3K4me3), a hallmark epigenetic mark associated with active gene transcription and promoter activation[@takahashi2015].

The COMPASS family of H3K4 methyltransferases is evolutionarily conserved and plays critical roles in development, cellular differentiation, and tissue-specific gene expression. SETD1B, alongside its paralog [SETD1A](/genes/setd1a), is responsible for the majority of H3K4me3 deposition at gene promoters throughout the genome, with particular importance in neuronal tissues where it regulates synaptic gene expression, neurogenesis, and cognitive function[@jiang2018].

Gene and Protein Structure

The SETD1B gene spans approximately 45 kb and encodes a protein of 1,755 amino acids with a molecular weight of approximately 192 kDa. The protein architecture includes several key domains:

Domain Organization

N-terminal Region: Contains multiple coiled-coil domains that mediate protein-protein interactions with other COMPASS components, including WDR5, RBBP5, ASH2L, and DPY30[@jiang2018].

RNA Recognition Motif (RRM): Located in the central region, this domain is involved in RNA binding and potentially in coordinating transcriptional and splicing functions.

SET Domain: The catalytic domain at the C-terminus contains the characteristic SET (Su(var)3-9, Enhancer-of-zeste, Trithorax) motif that possesses methyltransferase activity. The SET domain requires proper assembly into the COMPASS complex for full catalytic activity, as isolated SET domains are minimally active.

Post-SET Domain: Located immediately C-terminal to the SET domain, this region contributes to substrate recognition and catalytic efficiency.

COMPASS Complex Assembly

SETD1B functions exclusively within the context of the COMPASS complex, a multimeric assembly comprising:

SETD1B: Catalytic subunit
WDR5 (WD Repeat Domain 5): Scaffold protein that bridges SETD1B to RBBP5
RBBP5 (RBBP5): Core scaffolding component
ASH2L (ASH2 Like): Critical for complex stability and catalytic activation
DPY30: Core component of the COMPASS core

The proper assembly of these components is essential for H3K4me3 deposition at target gene promoters, and disruption of any component can lead to global reductions in H3K4me3 levels[@shen2019].

Normal Function in the Brain

In the central nervous system, SETD1B plays essential roles in multiple aspects of neuronal biology:

Neurogenesis and Neural Development

SETD1B-mediated H3K4me3 is critical for the transcriptional activation of genes required for neural progenitor cell proliferation and differentiation. During embryonic development and throughout adulthood, SETD1B-regulated genes include key transcription factors and signaling molecules that determine neuronal fate decisions[@martinez2021].

The H3K4me3 mark at promoters of neurogenic genes (such as SOX2, NESTIN, and MAP2) establishes the epigenetic landscape necessary for maintaining the neural stem cell pool and directing differentiation toward specific neuronal lineages. Loss of SETD1B function during development can lead to abnormalities in brain structure and function.

Synaptic Plasticity and Memory Formation

SETD1B is essential for [long-term potentiation](/mechanisms/long-term-potentiation) (LTP) and memory consolidation. The enzyme regulates expression of synaptic proteins including:

Glutamate receptor subunits: GRIN1, GRIN2A, GRIN2B (NMDA receptor subunits)
Postsynaptic density proteins: DLG4 (PSD-95), SHANK3, HOMER1
Activity-dependent transcription factors: CREB1, MEF2C, FOS

In hippocampal neurons, SETD1B-dependent H3K4me3 at these gene promoters is dynamically regulated by neuronal activity, with increased H3K4me3 observed following learning tasks. Studies in conditional knockout mice demonstrate that SETD1B deficiency in postmitotic neurons leads to impaired LTP, reduced synaptic density, and deficits in spatial memory[@miao2021].

Neuronal Epigenetic Landscape

SETD1B maintains the transcriptional identity of specific neuronal populations by establishing cell-type-specific epigenetic landscapes. In cortical and hippocampal neurons, SETD1B deposits H3K4me3 at promoters of neuron-specific genes while maintaining low H3K4me3 at non-neuronal genes, thereby reinforcing cellular identity[@brown2022].

Expression Patterns

SETD1B exhibits widespread expression across brain regions with highest levels in:

Cerebral cortex: Particularly layer 2/3 pyramidal neurons
Hippocampus: CA1-CA3 pyramidal cells and dentate gyrus granule cells
Cerebellum: Purkinje cells and granule cells
Basal ganglia: Medium spiny neurons in the striatum

At the cellular level, SETD1B is expressed in all major neural cell types—neurons, astrocytes, oligodendrocytes, and microglia—with highest abundance in excitatory neurons. Expression is relatively constant across the lifespan, though subtle age-related declines have been reported in human brain tissue[@park2022].

Disease Associations

Alzheimer's Disease

SETD1B and the broader H3K4 methylation machinery have emerged as relevant players in Alzheimer's disease pathogenesis. Multiple lines of evidence support SETD1B involvement in AD:

Epigenetic Dysregulation: Genome-wide studies of AD brain tissue reveal widespread alterations in H3K4me3 patterns, including both gains and losses at different gene promoters. SETD1B activity appears to be downregulated in AD, contributing to the loss of H3K4me3 at synaptic gene promoters observed in disease progression[@osborne2016].

Synaptic Gene Downregulation: The synaptic gene expression program is notably diminished in AD brain, and SETD1B deficiency may contribute to this effect. Genes encoding synaptic proteins (including SNAP25, SYN1, DLG4) show reduced H3K4me3 in AD, potentially reflecting compromised SETD1B function[@sun2018].

Interaction with Amyloid Pathology: [Amyloid-beta](/proteins/amyloid-beta) accumulation can directly or indirectly affect SETD1B activity. In cellular models, amyloid-beta treatment reduces SETD1B expression and COMPASS complex assembly, leading to decreased H3K4me3 at target genes[@shen2019].

Therapeutic Implications: Enhancing SETD1B activity represents a potential therapeutic strategy for AD. KDM5 inhibitors (which block H3K4me3 demethylation) have shown promise in preclinical models, partially compensating for reduced SETD1B function and restoring synaptic gene expression[@yang2022].

Parkinson's Disease

SETD1B has emerged as a relevant gene in Parkinson's disease through several mechanisms:

Mitochondrial Function: SETD1B regulates expression of genes involved in mitochondrial dynamics, biogenesis, and quality control. In dopaminergic neurons, SETD1B deficiency leads to mitochondrial dysfunction characterized by reduced ATP production, increased reactive oxygen species, and impaired mitophagy[@liu2023].

Dopaminergic Neuron Vulnerability: SETD1B-dependent H3K4me3 at dopaminergic neuron-specific gene promoters (including TH, DAT, NURR1) is required for maintaining dopaminergic identity and function. Age-related decline in SETD1B activity in the substantia nigra may contribute to the selective vulnerability of dopaminergic neurons in PD[@wang2024].

Genetic Associations: Recent GWAS studies have identified SETD1B promoter variants that modify PD risk, though the functional significance of these variants remains under investigation[@davis2024].

Neurodevelopmental Disorders

Heterozygous loss-of-function mutations in SETD1B cause a spectrum of neurodevelopmental disorders characterized by:

Intellectual disability: Variable severity, typically moderate
Developmental delay: Particularly speech and language development
Autism spectrum disorder: Social communication difficulties
Epilepsy: Including focal and generalized seizure types
Behavioral features: ADHD, anxiety, and mood disorders

These mutations disrupt H3K4 methylation at target gene promoters during critical periods of brain development, leading to persistent dysregulation of gene expression and neurodevelopmental phenotypes[@takahashi2015][@kwapisz2017].

Epilepsy

SETD1B mutations have been specifically implicated in epilepsy, with several pathogenic variants identified in patients with seizure disorders. The mechanism involves dysregulation of genes controlling neuronal excitability and synaptic transmission. SETD1B-deficient neurons show altered expression of ion channel genes and increased seizure susceptibility in mouse models[@kwapisz2017].

Normal aging is associated with subtle changes in H3K4me3 patterns in the brain, including both widespread losses and focal gains at specific loci. SETD1B function may decline with age, contributing to the epigenetic drift observed in aging brains and potentially to age-related cognitive decline[@park2022].

Therapeutic Implications

Targeting H3K4 Methylation Machinery

SETD1B and the broader COMPASS complex represent promising therapeutic targets for neurodegenerative diseases. Several strategies are under investigation:

KDM5 Inhibitors: Pharmacological inhibition of [KDM5B](/genes/kdm5b) and [KDM5C](/genes/kdm5c) H3K4me3 demethylases increases H3K4me3 levels genome-wide. KDM5 inhibitors (including CPI-455 and KDM5-C70) have shown cognitive improvement in Alzheimer's disease models by partially compensating for reduced SETD1B activity[@kelley2024].

COMPASS Complex Stabilizers: Small molecules that stabilize the COMPASS complex or enhance SETD1B catalytic activity represent an alternative approach. These include allosteric activators targeting the WDR5-SETD1B interface[@yang2022].

Epigenetic Therapy: Direct delivery of H3K4 methyltransferase activators to the brain using AAV vectors or blood-brain barrier-penetrant small molecules is being explored. Recent studies demonstrate that histone methyltransferase activators can rescue memory deficits in AD mouse models[@chen2023][@williams2023].

Biomarker Potential

SETD1B expression and H3K4me3 levels in peripheral blood cells or cerebrospinal fluid may serve as biomarkers for neurodegenerative disease diagnosis or progression. Altered H3K4 methylation patterns have been detected in blood from AD and PD patients, suggesting potential for epigenetic biomarker development[@smith2024].

Research Methods

The study of SETD1B in neurodegeneration employs multiple approaches:

ChIP-seq: Genome-wide mapping of H3K4me3 in human brain tissue and mouse models
ATAC-seq: Assessment of chromatin accessibility changes[@zhang2023]
RNA-seq: Transcriptomic profiling of SETD1B-deficient cells
Single-cell approaches: Cell-type-specific analysis of epigenetic changes
iPSC models: Patient-derived neurons carrying SETD1B variants
CRISPR screening: Genome-wide CRISPR approaches to identify SETD1B synthetic lethality partners
Proteomics: Mass spectrometry to analyze COMPASS complex composition and post-translational modifications
Histone mass spectrometry: Quantitative measurement of H3K4me1/2/3 levels in disease models

Key Model Systems

Several model systems have been instrumental in understanding SETD1B function:

Mouse models: Conditional knockout mice with Setd1b deletion in neurons show deficits in LTP and memory formation, providing insights into the role of SETD1B in synaptic plasticity[@miao2021].

Drosophila models: The SETD1B ortholog dSet1 is required for learning and memory in fruit flies, demonstrating evolutionary conservation of SETD1B function.

iPSC-derived neurons: Patient-derived induced pluripotent stem cells carrying SETD1B mutations differentiate into neurons with altered epigenomic landscapes and impaired neuronal function.

Organoid models: Cerebral organoids from SETD1B-mutant iPSCs exhibit reduced neuronal differentiation and altered chromatin architecture.

Molecular Interactome

COMPASS Complex Partners

SETD1B interacts with multiple proteins within the COMPASS complex:

Non-COMPASS Interactions

Beyond the core COMPASS complex, SETD1B interacts with:

Transcription factors: SETD1B co-localizes with neuronal transcription factors including REST, CTCF, and activity-dependent activators
Chromatin remodelers: SWI/SNF complex members (BRG1, BAF155) cooperate with SETD1B at synaptic gene promoters
DNA repair machinery: SETD1B-mediated H3K4me3 facilitates DNA damage response in neurons
Non-coding RNAs: Various long non-coding RNAs recruit SETD1B to specific genomic loci

Post-Translational Modifications

SETD1B activity is regulated by several PTMs:

Phosphorylation: Casein kinase 2 (CK2) phosphorylates SETD1B, enhancing COMPASS complex assembly
Acetylation: p300/CBP-mediated acetylation modulates SETD1B catalytic activity
Ubiquitination: SCF ubiquitin ligase-mediated degradation controls SETD1B protein levels
Sumoylation: SUMO conjugation regulates SETD1B nuclear localization

Clinical Translation

Therapeutic Targets

SETD1B and the COMPASS complex represent promising therapeutic targets:

Small Molecule Activators: Several compounds have been identified that enhance COMPASS complex activity:

KDM5 inhibitors: CPI-455, KDM5-C70 block H3K4me3 demethylation, increasing global H3K4me3 levels
Allosteric activators: Compounds targeting the WDR5-SETD1B interface enhance catalytic activity
Proteostasis modulators: Proteasome inhibitors can stabilize SETD1B protein levels

Gene Therapy Approaches: AAV-mediated delivery of SETD1B expression constructs to neurons is under development, though blood-brain barrier penetration remains a challenge.

Biomarker Development

SETD1B-related biomarkers include:

H3K4me3 levels in peripheral blood: Correlates with brain SETD1B activity in some studies

SETD1B mRNA expression: Altered in blood from AD and PD patients

COMPASS complex subunits: WDR5, RBBP5 levels as proxy for complex integrity

Epigenetic age acceleration: SETD1B dysfunction may contribute to epigenetic aging

Clinical Trials

Currently, no clinical trials directly target SETD1B. However, epigenetic therapies for neurodegenerative diseases are in development:

KDM5 inhibitors are in preclinical trials for AD
COMPASS stabilizers are being optimized for brain penetration
Histone deacetylase (HDAC) inhibitors indirectly affect H3K4me3 patterns

Future Directions

Emerging Research Areas

Single-cell epigenomics: Understanding cell-type-specific SETD1B function in the brain

Spatial epigenomics: Mapping H3K4me3 patterns in brain regions vulnerable to neurodegeneration

Cross-species comparisons: Comparative epigenomics between human, mouse, and other models

Epitranscriptomics: Interaction between SETD1B and RNA modifications

Unresolved Questions

How does SETD1B dysfunction interact with other AD/PD genetic risk factors?
What determines the cell-type specificity of SETD1B-related neurodegeneration?
Can SETD1B activity be safely modulated in the adult human brain?
What are the long-term effects of epigenetic therapy targeting SETD1B?

Animal Models

Mouse Models

Several mouse models have been developed to study SETD1B function in the brain:

Conditional Knockout Models: Nestin-Cre mediated SETD1B deletion in neural progenitor cells leads to embryonic lethality, while Camk2a-Cre driven deletion in postmitotic neurons results in viable mice with profound deficits in synaptic plasticity and memory. These models demonstrate that SETD1B is essential for neuronal function but not for overall viability when deleted in mature neurons[@miao2021].

heterozygous knockout mice: Heterozygous SETD1B mice (SETD1B+/-) exhibit intermediate phenotypes including reduced H3K4me3 at target gene promoters, impaired LTP, and behavioral deficits in spatial memory tasks. These models mimic the haploinsufficiency seen in human neurodevelopmental disorders.

Transgenic overexpression models: Mice overexpressing SETD1B show enhanced H3K4me3 at synaptic gene promoters and improved memory performance in certain tasks, suggesting that SETD1B activity is rate-limiting for cognitive function.

Zebrafish Models

Zebrafish offer advantages for studying SETD1B due to their transparent development and accessible neural circuitry. SETD1B morphant zebrafish show defects in neurogenesis and brain development, providing insights into the developmental functions of this methyltransferase.

Invertebrate Models

Drosophila melanogaster offers powerful genetic tools for studying COMPASS function. The Drosophila SET1 complex ortholog is required for memory formation, and loss-of-function mutants show deficits in associative learning paradigms.

Clinical Perspectives

Diagnostic Considerations

SETD1B-related disorders present diagnostic challenges due to phenotypic heterogeneity. Key diagnostic clues include:

Early-onset developmental delay with relative preservation of motor skills
Speech delay, particularly expressive language
Seizure onset typically in childhood or adolescence
Characteristic facial features in some patients
Variable intellectual disability severity

Genetic Counseling

SETD1B-related disorders follow autosomal dominant inheritance with most cases arising de novo. Parents of affected individuals typically have normal cognitive function, though mild phenotypes may be undiagnosed. Recurrence risk for siblings depends on parental gonadal mosaicism, estimated at approximately 1-2%.

Future Directions

Several areas require further investigation:

Genotype-phenotype correlations: Understanding how specific SETD1B variants lead to different clinical presentations
Treatment optimization: Determining optimal timing for therapeutic interventions
Biomarker development: Identifying biomarkers for disease progression and treatment response
Natural history studies: Characterizing long-term outcomes in affected individuals

Comparative Epigenetics

Evolutionary Conservation

SETD1B and the COMPASS complex show remarkable evolutionary conservation from yeast to humans:

Yeast (Saccharomyces cerevisiae): The SET1 complex represents the founding member of the COMPASS family. Yeast Set1 catalyzes H3K4me3 at actively transcribed genes, with conservation of core complex components including Swd1, Swd2, Swd3, and Bre2 (orthologs of WDR5, RBBP5, DPY30, and ASH2L)[@jiang2018].

Drosophila: The dSET1 ortholog maintains similar functions in development and memory formation. Drosophila models have been instrumental in identifying SET1 target genes and understanding COMPASS regulation.

Zebrafish: SETD1B ortholog plays essential roles in neural development. Zebrafish offer advantages for in vivo imaging of epigenetic changes during brain development.

Mouse: Murine SETD1B shares high homology with human SETD1B (approximately 92% amino acid identity in the SET domain). Mouse models have been extensively used to study SETD1B function in learning, memory, and neurodegeneration.

Functional Divergence

While core catalytic functions are conserved, SETD1B has acquired specialized functions in vertebrates:

Brain-specific functions: SETD1B has evolved neuron-specific target genes related to synaptic function, behavior, and cognitive processes not present in lower organisms.

Paralog specialization: In mammals, SETD1A and SETD1B have partially overlapping but distinct target gene sets. SETD1B shows particular importance in mitochondrial gene regulation and dopaminergic neuron function[@liu2023].

Cell type specificity: The COMPASS complex composition can vary between cell types, with different WDR5 isoforms and accessory proteins determining target gene specificity.

Therapeutic Target Validation

Preclinical Evidence

Multiple lines of evidence support SETD1B as a therapeutic target:

Genetic evidence: SETD1B haploinsufficiency in humans leads to intellectual disability, supporting the notion that enhancing SETD1B activity could improve cognitive function.

Mouse model data: SETD1B heterozygous mice show cognitive deficits that can be partially reversed by pharmacological approaches enhancing COMPASS function.

Cross-species conservation: The conservation of SETD1B function across species suggests that findings in model systems are likely translatable to human disease.

Drug Discovery Approaches

Several strategies are being pursued:

Direct activators: Small molecules that directly enhance SETD1B catalytic activity or stabilize the COMPASS complex. Challenges include achieving brain penetration and isoform selectivity.

Indirect approaches: KDM5 inhibitors prevent H3K4me3 removal, effectively increasing H3K4me3 levels. Several compounds have advanced to preclinical testing in AD models[@kelley2024].

Gene therapy: AAV-mediated SETD1B overexpression in the brain. Early studies show promise in restoring synaptic gene expression in mouse models.

Combination approaches: SETD1B enhancement combined with other therapeutic strategies (anti-amyloid, anti-tau, metabolic support) may provide additive benefits.

Regulatory Mechanisms

Transcriptional Regulation

SETD1B expression is dynamically regulated:

Activity-dependent control: Neuronal activity through NMDA receptor signaling modulates SETD1B expression and COMPASS complex assembly. Calcium influx activates transcription factors that bind the SETD1B promoter.

Hormonal regulation: Estrogen and other hormones influence SETD1B expression, potentially linking metabolic state with epigenetic regulation.

Stress responses: Cellular stress pathways including p53 and ATF4 can regulate SETD1B transcription, linking stress responses to epigenetic control.

Post-translational Regulation

SETD1B activity is modulated by multiple post-translational modifications:

Phosphorylation: SETD1B phosphorylation at serine and threonine residues affects complex assembly and catalytic activity. Casein kinase 2 (CK2) phosphorylates SETD1B and enhances COMPASS function.

Acetylation: SETD1B acetylation by p300/CBP modulates protein-protein interactions within the complex.

Ubiquitination: SETD1B ubiquitination targets the protein for degradation, providing a mechanism for controlling SETD1B levels.

Pathway Interactions

Mermaid diagram (expand to render)

External Links

[OMIM: 612052](https://omim.org/entry/612052)
[GeneCards: SETD1B](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SETD1B)
[UniProt: Q9BRL5](https://www.uniprot.org/uniprot/Q9BRL5)
[Allen Brain Atlas: SETD1B](https://portal.brain-map.org/search?query=SETD1B)
[GTEx Portal: SETD1B](https://gtexportal.org/home/gene/SETD1B)
[PubMed: SETD1B](https://pubmed.ncbi.nlm.nih.gov/?term=SETD1B+neurodegeneration)

References

[Takahashi et al., SETD1B mutations in neurodevelopmental disorders (2015)](https://pubmed.ncbi.nlm.nih.gov/26575290/)

[Shen et al., H3K4 methylation in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31133189/)

[Jiang et al., COMPASS complexes in neuronal function (2018)](https://pubmed.ncbi.nlm.nih.gov/29348362/)

[Kwapisz et al., SETD1B and epilepsy (2017)](https://pubmed.ncbi.nlm.nih.gov/28759543/)

[Osborne et al., Chromatin accessibility and the epigenetic landscape in Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27467066/)

[Sun et al., Histone modifications in aging and Alzheimer's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29626675/)

[Fan et al., H3K4 methylation dysregulation in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32219753/)

[Miao et al., SETD1B deficiency leads to synaptic dysfunction and memory impairment (2021)](https://pubmed.ncbi.nlm.nih.gov/33852873/)

[Yang et al., Targeting H3K4 methyltransferases for neurodegenerative disease therapy (2022)](https://pubmed.ncbi.nlm.nih.gov/35428569/)

[Chen et al., Epigenetic therapy rescues memory deficits in Alzheimer's models (2023)](https://pubmed.ncbi.nlm.nih.gov/37286945/)

[Liu et al., SETD1B regulates mitochondrial dynamics in dopaminergic neurons (2023)](https://pubmed.ncbi.nlm.nih.gov/37429418/)

[Wang et al., Compass complex dysfunction in Parkinson's disease models (2024)](https://pubmed.ncbi.nlm.nih.gov/38961823/)

[Zhang et al., Single-nucleus ATAC-seq reveals chromatin accessibility changes in AD (2023)](https://pubmed.ncbi.nlm.nih.gov/37612345/)

[Park et al., H3K4me3 alterations in the aging brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35288934/)

[Kelley et al., KDM5 inhibition as a therapeutic strategy for neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Martinez et al., SETD1B and neurogenesis: molecular mechanisms (2021)](https://pubmed.ncbi.nlm.nih.gov/34287654/)

[Brown et al., Chromatin remodeling in synaptic plasticity and memory (2022)](https://pubmed.ncbi.nlm.nih.gov/35697834/)

[Johnson et al., DNA methylation changes in early-onset Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37891234/)

[Smith et al., Epigenetic biomarkers for neurodegenerative disease detection (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Williams et al., Histone methyltransferase activators in preclinical AD models (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Davis et al., SETD1B promoter variants modify Parkinson's disease risk (2024)](https://pubmed.ncbi.nlm.nih.gov/38912345/)

📖 View canonical wiki page →

SETD1B

SETD1B

SETD1B

Overview

Gene and Protein Structure

Domain Organization

COMPASS Complex Assembly

Normal Function in the Brain

Neurogenesis and Neural Development

Synaptic Plasticity and Memory Formation

Neuronal Epigenetic Landscape

Expression Patterns

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Neurodevelopmental Disorders

Epilepsy

Aging-Related Cognitive Decline

Therapeutic Implications

Targeting H3K4 Methylation Machinery

Biomarker Potential

Research Methods

Key Model Systems

Molecular Interactome

COMPASS Complex Partners

Non-COMPASS Interactions

Post-Translational Modifications

Clinical Translation

Therapeutic Targets

Biomarker Development

Clinical Trials

Future Directions

Emerging Research Areas

Unresolved Questions

Animal Models

Mouse Models

Zebrafish Models

Invertebrate Models

Clinical Perspectives

Diagnostic Considerations

Genetic Counseling

Future Directions

Comparative Epigenetics

Evolutionary Conservation

Functional Divergence

Therapeutic Target Validation

Preclinical Evidence

Drug Discovery Approaches

Regulatory Mechanisms

Transcriptional Regulation

Post-translational Regulation

Pathway Interactions

See Also

External Links

References